🔎 Trials Near Me

Utama › Kanser Bronkus › Pennsylvania

Kajian klinikal Kanser Bronkus di Pennsylvania

5 kajian untuk Kanser Bronkus sedang mencari peserta di lokasi di Pennsylvania.

Bandar di Pennsylvania

Teks kajian rasmi (Bahasa Inggeris)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Allegheny Health Network, Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Alliance Cancer Specialists, PC, Horsham
  • Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • Fox Chase Cancer Center, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07185997

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Allegheny General Hospital, Natrona Heights
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT04614103

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

  • UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 11 Jun 2026 · NCT05361174

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.